Inamura Kentaro
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
Cancers (Basel). 2018 Apr 1;10(4):100. doi: 10.3390/cancers10040100.
Bladder cancer is one of the most prevalent cancers worldwide. Unfortunately, there have been few advances in its clinical management due to a poor understanding of the correlations between its molecular and clinical features. Mounting evidence suggests that bladder cancer comprises a group of molecularly heterogeneous diseases that undergo a variety of clinical courses and possess diverse therapeutic responses. Owing to the close association between its molecular subtypes and clinicopathological features, specific therapeutic strategies have recently been suggested. This review summarizes the current understanding of the molecular pathology of bladder cancer, including its molecular biomarkers/pathways and molecular subtypes that have been newly identified using high-throughput technologies. It also discusses advances in our understanding of personalized treatments for specific molecular subtypes.
膀胱癌是全球最常见的癌症之一。不幸的是，由于对其分子特征与临床特征之间的相关性了解不足，其临床管理进展甚微。越来越多的证据表明，膀胱癌是一组分子异质性疾病，经历多种临床病程，具有不同的治疗反应。由于其分子亚型与临床病理特征密切相关，最近有人提出了特定的治疗策略。本综述总结了目前对膀胱癌分子病理学的认识，包括其分子生物标志物/途径以及使用高通量技术新确定的分子亚型。它还讨论了我们在特定分子亚型个性化治疗理解方面的进展。
